MSTN and anemia: Counteraction of ACVR2B ligands was able to reverse anemia in C26 hosts independent of the administration protocol [13] and in inhibin-deficient mice [110], while ApcMin/+ mice presenting myostatin gene inactivation were also free from anemia [105].